Maravai LifeSciences Holdings, Inc. $MRVI Shares Bought by Monaco Asset Management SAM

Monaco Asset Management SAM boosted its position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 315.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,656,337 shares of the company’s stock after buying an additional 2,775,372 shares during the period. Maravai LifeSciences makes up approximately 0.6% of Monaco Asset Management SAM’s portfolio, making the stock its 8th biggest position. Monaco Asset Management SAM owned approximately 1.43% of Maravai LifeSciences worth $10,494,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in MRVI. Tejara Capital Ltd grew its stake in Maravai LifeSciences by 257.8% in the second quarter. Tejara Capital Ltd now owns 1,941,449 shares of the company’s stock valued at $4,679,000 after acquiring an additional 1,398,900 shares during the period. First Pacific Advisors LP bought a new position in shares of Maravai LifeSciences in the 2nd quarter worth $1,787,000. Immersion Corp lifted its holdings in shares of Maravai LifeSciences by 153.3% in the 2nd quarter. Immersion Corp now owns 990,000 shares of the company’s stock worth $2,388,000 after purchasing an additional 599,164 shares in the last quarter. Harspring Capital Management LLC acquired a new stake in Maravai LifeSciences in the 2nd quarter valued at $1,205,000. Finally, Jane Street Group LLC increased its stake in Maravai LifeSciences by 1,463.1% during the 1st quarter. Jane Street Group LLC now owns 380,403 shares of the company’s stock valued at $841,000 after purchasing an additional 356,067 shares in the last quarter. 50.25% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Wells Fargo & Company raised their price objective on shares of Maravai LifeSciences from $4.00 to $4.50 and gave the company an “overweight” rating in a research note on Monday, December 15th. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Maravai LifeSciences currently has a consensus rating of “Hold” and an average price target of $5.25.

Maravai LifeSciences Trading Up 0.6%

NASDAQ MRVI opened at $3.10 on Friday. The company has a current ratio of 5.29, a quick ratio of 4.56 and a debt-to-equity ratio of 0.74. The business has a fifty day simple moving average of $3.46 and a 200 day simple moving average of $3.16. Maravai LifeSciences Holdings, Inc. has a 12 month low of $1.66 and a 12 month high of $4.30. The firm has a market capitalization of $792.70 million, a P/E ratio of -3.69 and a beta of 0.39.

Insiders Place Their Bets

In other news, Director Gregory T. Lucier acquired 51,472 shares of Maravai LifeSciences stock in a transaction on Friday, December 5th. The stock was acquired at an average cost of $3.70 per share, with a total value of $190,446.40. Following the transaction, the director owned 106,595 shares of the company’s stock, valued at approximately $394,401.50. This trade represents a 93.38% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 2.11% of the company’s stock.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.